about
A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial VirusStructural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvMaturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic AntibodyDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesVaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A VirusesStructures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designStructure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial VirusTrimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and GSomatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing AntibodiesTransplanting supersites of HIV-1 vulnerability.Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Structure and immune recognition of trimeric pre-fusion HIV-1 Env.Conformational dynamics in loop swap mutants of homologous fibronectin type III domains.Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1.Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts.Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.Microsecond Dynamics and Network Analysis of the HIV-1 SOSIP Env Trimer Reveal Collective Behavior and Conserved Microdomains of the Glycan Shield.Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.Insights from NMR Spectroscopy into the Conformational Properties of Man-9 and Its Recognition by Two HIV Binding Proteins.CD4-binding-Site Recognition by VH1-46 Germline-derived HIV-1 Neutralizers.Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loopRole of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failureProlonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccineGlycosylator: a Python framework for the rapid modeling of glycansHuman VH1-69 Gene-Encoded Human Monoclonal Antibodies against Staphylococcus aureus IsdB Use at Least Three Distinct Modes of Binding To Inhibit Bacterial Growth and PathogenesisHigh frequency of shared clonotypes in human B cell receptor repertoiresImmune repertoire fingerprinting by principal component analysis reveals shared features in subject groups with common exposuresHuman-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoiresIntegrated technology platform for accelerated discovery of antiviral antibody therapeutics
P50
Q27305097-837F97F5-8CA4-4033-909E-C0735A6956B2Q27643993-EB96F262-C5BC-4F3D-9C79-4FE30886E3DFQ27644383-4A4F0058-3C18-4525-AD31-9F4DCC868AD4Q27644415-704E38BA-6003-44A4-8CA9-59B09AD8D9BCQ27644515-69852AB5-0EB4-41AD-8372-8DA27FA96814Q27644544-36D5C6C4-8A84-4701-AC4B-9176CF720387Q27644634-BEBF9320-45B4-449E-ACFF-2983206C8A12Q27680499-05EEA38D-185C-4124-B4B6-34F37103BBACQ27704710-95E5729C-969C-43FF-9597-A6C660E6B3ACQ27723297-6958A8A5-8C73-432C-9441-FD39BB95AAA2Q33854841-E6FE08E3-2F6A-46C2-AC4F-39FD4DC0BFB6Q34526404-4611D174-1F21-49CC-86AC-BD27ADC5AB19Q34593860-B5E8C395-D6EA-4097-B866-5CD46122F47CQ35142291-3621A689-47FF-4F0F-BCF7-CF13D59C42E2Q35972988-22724D74-B81F-4FFE-8B85-3068FBC528BCQ36051588-86684D85-808C-4214-B451-0BD66D84CAEEQ36263513-187411E3-405A-4581-9D7C-F25A889A534EQ36444787-50C3EF0C-1A06-4F44-B86E-24CCC97EBFEFQ37242530-EBD08F89-3579-49F5-AB50-DEDC6F1E7B21Q37255993-4D00A9E5-426C-49C3-8966-E144AA7433ACQ37830140-361F08BC-673A-4C57-AF2F-C3CFB843C28FQ40048712-37C8A565-2754-41C8-A936-E31B719D6C47Q40226810-B9F3CD9B-F1B9-4DB3-9350-E7868B0B7C5FQ40343366-7AE9F6A8-9297-4C7E-84F0-5A78D9598921Q55637932-3927F29F-12B3-4CF2-885D-FEAD13116667Q57091851-C1DA73CE-ED1F-4C89-BBF8-0957591BCB13Q59351218-6E05546C-4027-450C-A218-BFD90A91FBE2Q64374712-D36F1BEF-A3DE-482E-81E9-9BF5F3BB37F7Q90879476-86ED413C-29DB-455A-B5DD-78999F92A006Q90883532-B58D9797-2E42-433D-A5BA-5F10FE8B0319Q91560038-9EA06DBE-5669-4ED1-BA76-DEBB8AB69F05Q91694585-F2B87428-080D-4533-A851-AF9F36C9DC47Q94594250-C40A9AFB-C8AD-4641-B08A-AB9F610676C1Q95601420-6890EC9C-C6DD-452D-9F12-93783C6D0188
P50
description
pediatric researcher
@en
name
Cinque Soto
@en
type
label
Cinque Soto
@en
prefLabel
Cinque Soto
@en
P21
P31
P496
0000-0002-3997-6217